ଡେଫେରିପ୍ରୋନ

ଡେଫେରିପ୍ରୋନ
Clinical data
Trade names	Ferriprox
AHFS/Drugs.com	monograph
MedlinePlus	a612016
data	EU EMA: yes; US DailyMed: Deferiprone;
Pregnancy; category	AU: D ; US: D (Evidence of risk) ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) / P; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Metabolism	Glucuronidation
Elimination half-life	2 to 3 hours
Excretion	Kidney (75 to 90% in 24 hours)
Identifiers
	IUPAC name 3-hydroxy-1,2-dimethylpyridin-4(1H)-one;
ECHA InfoCard	100.157.470
Chemical and physical data
Formula	C7H9NO2
Molar mass	୧୩୯.୧୫ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C\1C(\O)=C(/N(/C=C/1)C)C;
	InChI InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3 ; Key:TZXKOCQBRNJULO-UHFFFAOYSA-N ;
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Deferiprone

ଡେଫେରିପ୍ରୋନ ଇଂରାଜୀ ଭାଷାରେ Deferiprone, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଫେରିପ୍ରୋକ୍ସ ବ୍ରାଣ୍ଡ ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଥାଲାସେମିଆ ମେଜରରେ ରକ୍ତଦାନ ହେତୁ ଲୌହ ଅତିଭାରର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ^[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୫] ଉନ୍ନତ ରକ୍ତ ଚିହ୍ନର ପ୍ରମାଣ‌କୁ ସମର୍ଥନ କରେ କିନ୍ତୁ ଲକ୍ଷଣ କିମ୍ବା ବଞ୍ଚିବା ନୁହେଁ । ^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଲାଲ-ବାଦାମୀ ପରିସ୍ରା, ଅଇ, ପେଟ ଯନ୍ତ୍ରଣା ଏବଂ ବାନ୍ତି ହୋଇପାରେ ।^[୩] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସ୍ୱଳ୍ପ ଶ୍ୱେତ ରକ୍ତ କଣିକା, ସଂକ୍ରମଣ ଏବଂ ଦୀର୍ଘସ୍ଥାୟୀ କ୍ୟୁଟି ବା ଲଙ୍ଗ କ୍ୟୁଟି ସିଣ୍ଡ୍ରୋମ ହୋଇପାରେ ।^[୩] ^[୪] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୪] ଏହା ଏକ ଲୁହା ଚିଲେଟର । ^[୩]

୧୯୯୪ ମସିହାରେ ବ୍ୟବସାୟିକ ଭାବରେ ଡେଫେରିପ୍ରୋନ ଉପଲବ୍ଧ ହେଲା ^[୬] ଏହା ପ୍ରଥମେ ୟୁରୋପ ଏବଂ ଏସିଆରେ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୭] ଡିଫେରେସିରକ୍ସର ବିକଳ୍ପ ଭାବରେ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଜରୁରୀ ଔଷଧ ତାଲିକାରେ ଏହାର ନାମ ଲିପିବଦ୍ଧ ଅଛି ।^[୮] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।^[୫] ପରେ ଏହା ୨୦୧୧ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ୫୦୦ ମିଗ୍ରା ବିଶିଷ୍ଟ ୧୦୦ ବଟିକା ମୂଲ୍ୟ ପ୍ରାୟ ୧୩୦ ପାଉଣ୍ଡ ଥିଲା ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୭,୫୦୦ ଡଲାର ଅଟେ ।^[୯]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Deferiprone (Ferriprox) Use During Pregnancy". Drugs.com. 30 March 2020. Archived from the original on 26 October 2020. Retrieved 20 May 2020.
↑ "Ferriprox 100 mg/ml oral solution - Summary of Product Characteristics (SmPC)". (emc). 26 November 2019. Archived from the original on 7 August 2020. Retrieved 20 May 2020.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Ferriprox EPAR". European Medicines Agency (EMA). Archived from the original on 14 August 2020. Retrieved 20 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Deferiprone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 June 2021. Retrieved 21 December 2021.
↑ ^୫.୦ ^୫.୧ ^୫.୨ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1075. ISBN 978-0857114105.
↑ Staff. "Cipla's History". Cipla. Archived from the original on 2015-10-27.
↑ Savulescu J (February 2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.
↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
↑ "Ferriprox Prices, Coupons and Patient Assistance Programs". Retrieved 22 December 2021.

[Drugs.com_pregnancy-1] ୧.୦ ^୧.୧ "Deferiprone (Ferriprox) Use During Pregnancy". Drugs.com. 30 March 2020. Archived from the original on 26 October 2020. Retrieved 20 May 2020.

[2] "Ferriprox 100 mg/ml oral solution - Summary of Product Characteristics (SmPC)". (emc). 26 November 2019. Archived from the original on 7 August 2020. Retrieved 20 May 2020.

[EPAR2021-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Ferriprox EPAR". European Medicines Agency (EMA). Archived from the original on 14 August 2020. Retrieved 20 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[AHFS2021-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Deferiprone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 June 2021. Retrieved 21 December 2021.

[BNF81-5] ୫.୦ ^୫.୧ ^୫.୨ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1075. ISBN 978-0857114105.

[6] Staff. "Cipla's History". Cipla. Archived from the original on 2015-10-27.

[BMJ2004-7] Savulescu J (February 2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.

[WHO23rd-8] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[9] "Ferriprox Prices, Coupons and Patient Assistance Programs". Retrieved 22 December 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]